A Davie mom fighting a rare and rapidly spreading cancer is enrolled in a pioneering clinical trial at Memorial Cancer ...

Johnson & Johnson MedTech, a global leader in breast aesthetics and reconstruction1, today announced the U.S. launch of MENTOR™ MemoryGel™ Enhance Breast Implants, filling a critical gap in ...

Abeona Therapeutics Inc. (Nasdaq: ABEO) and Ann & Robert H. Lurie Children’s Hospital of Chicago today announced that Lurie Children’s is now activated as the first Qualified Treatment Center (QTC) ...

Weight-loss drugs and bariatric surgery both have an impact on cancer risk. A new study breaks down the link and how GLP-1 ...

The FDA has approved Teal Health's at-home test for HPV detection, which may help expand access to cervical cancer screening ...

Several ASX-listed companies have partnered with Cell Therapies, based at Peter Mac – Australia’s only facility capable of ...

The FDA has granted Orphan Drug designation to TPST-1495, dual receptor inhibitor of prostaglandin signaling, for the treatment of familial adenomatous polyposis.

BofA Securities 2025 Healthcare Conference May 13, 2025 1:40 PM ETCompany ParticipantsJohn Reed - Executive Vice ...

Penpulimab-kcqx, a humanized immunoglobulin G1 monoclonal antibody, blocks the interaction between the programmed death 1 receptor on T-cells and programmed death ligand 1 and 2 on tumor cells.

Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.

A new treatment approach significantly improves survival rates for patients with aggressive, inherited breast cancers, according to researchers. In a trial where cancers were treated with chemotherapy ...